

# Leprosy/Hansen Disease: Management of reactions and prevention of disabilities

Technical guidance





# **Leprosy/Hansen Disease: Management of reactions and prevention of disabilities**

**Technical guidance**



**World Health  
Organization**

Leprosy/Hansen Disease: Management of reactions and prevention of disabilities. Technical guidance  
ISBN: 978-92-9022-759-5

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Leprosy/Hansen Disease: Management of reactions and prevention of disabilities. Technical guidance. New Delhi: World Health Organization, Regional Office for South-East Asia; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in India.

# Contents

<i>Contributors</i> .....	v
<i>Abbreviations</i> .....	vi
<i>Foreword</i> .....	vii
<i>Executive summary</i> .....	viii
1. An introduction to leprosy reactions and neuritis.....	1
1.1 Background .....	1
1.2 Definitions of terms.....	2
1.3 Type 1 reactions and neuritis.....	3
1.4 Type 2 reaction .....	8
1.5 Neuropathic pain.....	10
1.6 Disability-adjusted life years in leprosy .....	10
2. Nerve function assessment in leprosy .....	11
2.1 Introduction to nerve function assessment.....	11
2.2 Sensory testing.....	13
2.3 Voluntary muscle testing .....	15
3. Medical management of reactions and neuritis in leprosy.....	17
3.1 Treatment of Type 1 reaction and neuritis.....	17
3.2 Treatment of Type 2 reaction.....	21
3.3 Treatment of reactions: summary .....	25
4. Managing reactions and neuritis: Step-by-step approach.....	26
4.1 Principals of managing reactions and neuritis .....	26
4.2 The four steps in managing leprosy reactions.....	28
4.3 Counseling and health promotion .....	30
5. Algorithms for managing persons with leprosy in a clinical setting.....	31
5.1 Algorithm 1: Recognizing when a reaction is present.....	31
5.2 Algorithm 2: Knowing whether a reaction is Type 1 or Type 2 .....	32
5.3 Algorithm 3: Testing nerve function .....	33

5.4.	Algorithm 4: Treating Type 1 reaction and neuritis.....	34
5.5.	Algorithm 5: Follow up of patients with Type 1 reaction and neuritis .....	35
5.6.	Algorithm 6: Starting treatment for Type 2 reaction .....	37
5.7.	Algorithm 7: Follow up of patients with Type 2 reaction .....	39
6.	Key facts to remember .....	40
7.	References.....	42

### **Annexes**

1.	ENLIST ENL Severity Scale .....	50
2.	Model Leprosy Patient Card.....	53
3.	Further guidance on thalidomide for the treatment of ENL reactions .....	61

# Contributors

N. Agebigo (Papua New Guinea)  
M. Balagon (the Philippines)  
J. Barreto (Brazil)  
T. Bauru (Kiribati)  
A. Beshah (Congo)  
J. Brandão (Brazil)  
T. Budiawan (Indonesia)  
J. Chukwu (Nigeria)  
E. Cooreman (India)  
M. Da Palma Caldas (Angola)  
J. Darlong (India)  
S. Dogra (India)  
F. D. H. Estrada (the Philippines)  
O. Faye (Mali)  
A. Fomba (Mali)  
M. D. Gupte (India)  
K. Itoh (Japan)  
K. Jetton (Marshall Islands)  
A. John (India)  
R. C. Johnson (Benin)  
J. Joshua (India)  
E. Keller (Federated States of Micronesia)  
S. Lambert (Ethiopia)  
L. Lehman (Brazil)  
D. Lockwood (United Kingdom)  
A. Maghanoy (the Philippines)  
M. Murhekar (India)  
V. Narsappa (India)  
M. Nobre (Brazil)  
S. K. Noordeen (India)  
V.V. Pai (India)  
T. T. Pakasi (Indonesia)  
V. Pannikar (India)  
S. Paul (India)  
V. R. R. Pemmaraju (India)  
S. Pennini (Brazil)  
M. Puri (Nepal)  
B. Quao (Ghana)  
K. Rahevar (the Philippines)  
J. Richardus (the Netherlands)  
Y. Rie (Japan)  
I. Roger (Brazil)  
M. Roses (Argentina)  
P. Saunderson (Norway)  
S. Sermittirong (Thailand)  
V. Shetty (India)  
G. Sridevi (India)  
R. S. Nicholls (United States of America)  
A. Srikantam (India)  
K. Stanley (India)  
T. Tadesse (Ethiopia)  
A. Tobiki (Japan)  
S. Warusavithana (Egypt)  
S. L. S. Watdhani (Indonesia)  
N. Vera (Colombia)  
C. Wiens (Paraguay)  
Zaw Lin (India)

# Abbreviations

---

BI	bacillary index
BL	borderline-lepromatous
DALY	disability-adjusted life year
ENL	<i>erythema nodosum leprosum</i>
ENLIST	ENL International Study Group
ILEP	International Federation of Anti-Leprosy Associations
LL	lepromatous
<i>M. leprae</i>	<i>Mycobacterium leprae</i>
MB	multibacillary
MDT	multidrug therapy
MRC	Medical Research Council
NFI	nerve function impairment
NSAID	non-steroidal anti-inflammatory drug
PB	paucibacillary
ST	sensory testing

预览已结束，完整报告链接

<https://www.yunbaogao.cn/report/index/re>